RT Journal Article
SR Electronic
T1 Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.29.21264325
DO 10.1101/2021.09.29.21264325
A1 Levin, Andrew
A1 Owusu-Boaitey, Nana
A1 Pugh, Sierra
A1 Fosdick, Bailey K.
A1 Zwi, Anthony B.
A1 Malani, Anup
A1 Soman, Satej
A1 Besançon, Lonni
A1 Kashnitsky, Ilya
A1 Ganesh, Sachin
A1 McLaughlin, Aloysius
A1 Song, Gayeong
A1 Uhm, Rine
A1 Meyerowitz-Katz, Gideon
YR 2021
UL http://medrxiv.org/content/early/2021/11/03/2021.09.29.21264325.abstract
AB Introduction The infection-fatality rate (IFR) of COVID-19 has been carefully measured and analyzed in high-income countries, whereas there has been no systematic analysis of age-specific seroprevalence or IFR for developing countries. Indeed, it has been suggested that the death rate in developing countries may be far lower than in high-income countries—an outcome that would be starkly different from the typical pattern for many other infectious diseases.Methods We systematically reviewed the literature to identify all serology studies in developing countries that were conducted using representative samples of specimens collected by early 2021. For each of the antibody assays used in these serology studies, we identified data on assay characteristics, including the extent of seroreversion over time. We analyzed the serology data using a Bayesian model that incorporates conventional sampling uncertainty as well as uncertainties about assay sensitivity and specificity. We then calculated IFRs using individual case reports or aggregated public health updates, including age-specific estimates whenever feasible.Results Seroprevalence in many developing country locations was markedly higher than in high-income countries but still far short of herd immunity. In most locations, seroprevalence among older adults was similar to that of younger age-groups. Age-specific IFRs were 1.3-2.5x higher than in high-income countries. The median value of population IFR was 0.5% among developing countries with satisfactory death reporting as of 2016, compared to a median of 0.05% for other developing countries.Conclusion The burden of COVID-19 is far higher in developing countries than in high-income countries, reflecting a combination of elevated transmission to middle-aged and older adults as well as limited access to adequate healthcare. These results underscore the critical need to accelerate the provision of vaccine doses to vulnerable populations in developing countries.Key Points- Age-specific prevalence and infection fatality rate (IFR) of COVID-19 for developing countries has not been well assessed.- Seroprevalence in developing countries (as measured by antibodies against SARS-CoV-2) is markedly higher than in high-income countries but still far short of herd immunity.- Seroprevalence among older adults is broadly similar to that of younger age-groups.- Age-specific IFRs in developing countries are roughly twice those of high-income countries.- Population IFR in developing countries with satisfactory death reporting (based on Global Burden of Disease data as of 2019) is ten times higher than in other developing countries.- These results underscore the urgency of disseminating vaccines to vulnerable people in developing countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research required no ethical approvalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code are available online at https://covid-ifr.github.io/